8/20/2019 Abprofilactico Cesarea
1/40
ANTIBIOTIC PROPHYLAXIS REGIMENS AND DRUGS FOR CESAREANSECTION
Hopkins L, Smaill F
Date of most recent substantive amendment: 1 November 1998This review should be cited as: Hopkins L, maill !" #ntibiotic proph$la%is re&imens and dru&s for cesareansection '(ochrane )eview*" +n: The Cochrane Library , +ssue 1, --." /%ford: 0pdate oftware"
• end feedback about this document
A B S T R A C T
Bak!"o#n$
roph$lactic antibiotics for cesarean section have been shown to reduce the incidence of maternalpostoperative infectious morbidit$" 2an$ different antibiotic re&imens have been reported to be
effective"
O%&'(i)'s
The ob3ective of this review was to determine which antibiotic re&imen is most effective inreducin& the incidence of infectious morbidit$ in women under&oin& cesarean section"
S'a"* S("a('!+4e searched the (ochrane re&nanc$ and (hildbirth 5roup trials re&ister and the (ochrane
(ontrolled Trials )e&ister" The date of the most recent search was /ctober 1998"
S'l'(ion C"i('"ia
)andomi6ed trials that included women under&oin& cesarean section were included" Trials werere7uired to compare at least two different antibiotic re&imens" Trials that compared placebo with a
sin&le antibiotic re&imen were not included as these are studies which have been anal$6ed inanother (ochrane review"
Da(a oll'(ion an$ anal+sisData were e%tracted from each publication independentl$ b$ the reviewers" )eviewers were notblinded to the authors or sources of the articles" The primar$ outcome variable was endometritis
but data on other infectious complications were collected where provided"
Main R's#l(s
!ift$one trials published between 199 and 199 were included in the review and four weree%cluded from the review" The followin& results refer to reductions in the incidence ofendometritis" ;oth ampicillin and first &eneration cephalosporins have similar efficac$ with an odds
ratio '/)* of 1" '9
8/20/2019 Abprofilactico Cesarea
2/40
endometritis and wound infection for women havin& elective 'planned* cesarean section as well as
those havin& emer&enc$ procedures 'adilla 198.? 2ohamed 1988*"
4hile it is clear that women under&oin& cesarean section benefit from proph$lactic antibiotics, it is
not clear whether an$ one particular a&ent is the dru& of choice" 2an$ different dru& re&imenshave been reported to be effective in decreasin& postoperative infectious morbidit$" To date,
penicillin, ampicillin, ticarcillin, me6locillin, piperacillin, imipenam, metronida6ole, clindam$cin,
&entamicin, tobram$cin, cefa6olin, cephalothin, ceforanide, cefonicid, cefuro%ime, cefta6idime,cefo%itin, cefamandole, cephradine, cefotetan and cefota%ime have been used for cesarean sectionproph$la%is and all have demonstrated efficac$ either alone or in combination with another dru&"
ome of these dru&s have activit$ a&ainst a narrow ran&e of potential patho&ens 'e&metronida6ole, &entamicin*, others specificall$ have additional anaerobic activit$ 'e& cefo%itin and
cefotetan* and $et others have ver$ broadspectrum covera&e 'imipenem*" Their pharmacokineticproperties 'e& serum half life* also differ"
ince there are an overwhelmin& number of effective dru&s available attempts to define anantibiotic re&imen of choice have been problematic" +deall$, such a dru& re&imen should be: '1*
proven effective in welldesi&ned prospective, randomi6ed, doubleblind clinical trials, '* activea&ainst the ma3orit$ of patho&ens likel$ to be involved, '.* attain ade7uate serum and tissue
levels throu&hout the procedure, '* not associated with the development of antimicrobialresistance, '
8/20/2019 Abprofilactico Cesarea
3/40
+n addition, data were collected 'where available* on adverse events of treatment 'e& aller&ic and
other to%ic reactions, antibiotic associated diarrhea, development of bacterial resistance*,maternal len&th of sta$ and costs, and neonatal outcomes"
S E A R C H S T R A T E G Y F O R I D E N T I F I C A T I O N O F S T U D I E S
ee: (ochrane re&nanc$ and (hildbirth 5roup search strate&$
This review has drawn on the search strate&$ developed b$ the re&nanc$ and (hildbirth 5roup asa whole" The primar$ source of studies was the review &roup@s trials re&ister the re&nanc$ and(hildbirth 5roup@s peciali6ed )e&ister of controlled trials" ee )eview 5roup@s details for more
information" +n addition, the (ochrane (ontrolled Trials )e&ister was searched" The date of lastsearch was /ctober 1998"
M E T H O D S O F T H E R E V I E W
#ll potential trials were selected for eli&ibilit$ accordin& to the criteria specified in the protocol anddata were e%tracted from each publication b$ two reviewers" #n$ discrepancies were resolved b$discussion" +n addition to the main outcome measures listed above, information on the settin& ofthe stud$ 'countr$, t$pe of population, socioeconomic status*, a detailed description of the
antibiotic re&imen used 'dru&, dose, fre7uenc$ and timin&*, and definitions of the outcomes 'ifprovided* were collected" #n intent to treat anal$sis was performed where possible"
Trials were assessed for methodolo&ical 7ualit$ usin& the standard (ochrane criteria of ade7uac$of allocation concealment: ade7uate '#*, unclear ';*, inade7uate '(*, or that allocation
concealment was not used 'D*" +nformation on blindin& of outcome assessment and loss to followup were collected"
The main comparison of an$ treatment versus another treatment will not be stratified accordin& tothe indication for cesarean section"
eparate comparisons of different antimicrobial re&imens, &rouped where appropriate b$ spectrumof activit$, were made" +f there were sufficient trials, separate comparisons were made between
the timin& of antibiotic administration, the number of doses &iven and the route of administration'whether s$stemic or lava&e*"
ummar$ relative risks were calculated usin& a fi%ed effects model 'if there is no si&nificanthetero&eneit$ between trials*"
D E S C R I P T I O N O F S T U D I E S
!or a detailed description of studies see table of @ (haracteristics of included studies@"
#ll fift$one trials included in the review were conducted in industriali6ed countries '0nited tates,(anada, +srael, +tal$, wit6erland or The Netherlands*" (riteria listed to define the presence of
outcome variables of interest 'e& endometritis* were remarkabl$ consistent across trials"#ntibiotics for proph$la%is were administered after the cord was clamped in all but three of thetrials" The antimicrobial a&ents used in the trials included ampicillin, penicillin, imipenem,
cefa6olin, cephalothin, cephapirin, cefotetan, cefamandole, cefuro%ime, cefmeta6ole, cefo%itin,piperacillin, cefota%ime, cefta6idime, ceftria%one, me6locillin, mo%alactam, cefonicid, cefti6o%ime,
ticarcillin, &entamicin, clindam$cin, ceforanide, and metronida6ole" Two studies were published inthe 19-s, thirt$seven in the 198-s and twelve in the 199-s" /nl$ three studies could be found
that were eli&ible for inclusion where proph$lactic antibiotics were administered preoperativel$"The vast ma3orit$ of studies that administered proph$lactic antibiotics preoperativel$ were
placebocontrol trials with no additional treatment arms" Therefore, these studies were not eli&iblefor inclusion"
M E T H O D O L O G I C A L Q U A L I T Y!or detailed information on methods, see table of @(haracteristics of included studies@"
The methodolo&ical 7ualit$ of the studies overall was e%cellent" #lmost all of the studies were
intention to treat anal$ses and for some, it was possible to convert them where necessar$ datawas included"
R E S U L T S
The results of the metaanal$sis indicate that both ampicillin and first &eneration cephalosporinshave similar efficac$ in the reduction of maternal infectious morbidit$ followin& cesarean section"
!urther, it is not onl$ the relativel$ minor outcomes of febrile morbidit$ and endometritis that aree7uivalent with the different antibiotic re&imens, but serious infections as well" There is no
evidence that a more broadspectrum a&ent produces &reater efficac$ in the reduction ofinfectious morbidit$ followin& cesarean section" There is no evidence from this metaanal$sis to
recommend multiple doses of antibiotics" There appears to be no difference in efficac$ based on
whether the antibiotic is administered s$stemicall$ or b$ a lava&e route" There is insufficientevidence upon which to base a recommendation re&ardin& the optimal timin& of administration"
8/20/2019 Abprofilactico Cesarea
4/40
D I S C U S S I O N
#ntibiotic proph$la%is can be e%pected to produce a si&nificant reduction in the incidence of
maternal infectious morbidit$" The t$pe of a&ent used proph$lacticall$ as well as the optimaltimin& of administration have been widel$ studied and discussed in the literature" +t is interestin&
to note that ver$ few trials have been published since the late 198-s on this sub3ect"
The results of this review indicate that both ampicillin and first &eneration cephalosporins are
appropriate choices for antibiotic proph$la%is for cesarean section" $stemic administration ofthese a&ents is recommended based on the results of this review"
The results indicate that a multiple dose re&imen does not offer an$ added benefit when comparedwith sin&le dose re&imens" !urthermore, sin&le dose re&imens are likel$ to be less e%pensive" The
advanta&es of a sin&le dose re&imen are obvious and mi&ht ensure universal utili6ation ofproph$lactic antibiotics for cesarean section, especiall$ in underresourced countries"
There is insufficient data upon which to offer a recommendation concernin& timin& ofadministration 'preoperative versus after cord clampin&* of proph$lactic antibiotics for cesarean
section" Nearl$ all published trials since 198 have administered the antimicrobial a&entimmediatel$ after the cord is clamped" rior to this, proph$lactic a&ents were adminstered pre
operativel$" This rather abrupt chan&e in practice followed the publication of prospectiverandomi6ed, placebo controlled trial demonstratin& that proph$lactic ampicillin administered after
the cord was clamped was as effective in decreasin& maternal morbidit$ as ampicillin &iven prior tothe procedure '5ordon 199*" 0nfortunatel$, no stud$ of sufficient si6e has $et been published
indicatin& whether preoperative administration or administration after the cord is clamped is moreeffective" 0ntil more evidence is available, timin& of administration ma$ remain discretionar$" Themost important &oal should be to ensure that all women under&oin& cesarean section receiveproph$lactic antibiotics and the a&ent of choice should be either ampicillin or a first &eneration
cephalosporin" (lindam$cin is an appropriate alternate choice for penicillinaller&ic women"
R E V I E W E R ' S C O N C L U S I O N S
Implia(ions /o" p"a(i';oth ampicillin and first &eneration cephalosporins represent &ood choices for proph$la%is in
women under&oin& cesarean section" 2ore costl$ e%tendedspectrum penicillins, second or third&eneration cephalosporins and combination re&imens have not been demonstrated to be more
effective" There is no evidence to su&&est that a multiple dose re&imen is of &reater benefit to thewoman than a sin&ledose re&imen"
Implia(ions /o" "'s'a"*
There will continue to be debate both in the literature and in clinical practice re&ardin& the optimaltime for administration of proph$lactic antibiotics" There is currentl$ insufficient evidence upon
which to base a recommendation re&ardin& the optimal timin& of antibiotic administration" This7uestion will not be resolved until a randomi6ed trial of sufficient si6e is completed comparin& pre
operative administration versus administration immediatel$ after the cord is clamped"
A C K N O W L E D G E M E N T S
None"
P O T E N T I A L C O N F L I C T O F I N T E R E S T
None known"
T A B L E S
C*a"a('"is(is o/ inl#$'$ s(#$i's
Detach table
S(#$+ B'ni!o 0123
2ethods )andomi6ed, double blind stud$"
articipants 4omen under&oin& (A"
NB.> enrolled: 5roup 1, NB1>9 vs 5roup , NB1"
Total >. women e%cluded because of e%clusion criteria and loss to followup '5roup 1,NB.. and 5roup , NB.-*"
C%clusion criteria: antibiotic use in last da$s, dru& aller&$, renal or hepatic d$sfunction,infection at time of enrollment, intention to breast feed within hours of deliver$"
8/20/2019 Abprofilactico Cesarea
5/40
+nterventions 5roup 1: & iv piperacillin after cord clamped with repeat doses at and 8 hours post
first dose"
5roup : & cefo%itin after cord clamped with repeat doses at and 8 hours postfirst
dose"
/utcomes !ebrile morbidit$ 'temp .8 % occasions, > hours apart, not included first hour postoperation
5roup 1: -A1.> vs 5roup : >A1"
4ound infection 'criteria not specified*
5roup 1: 1A1.> vs 5roup : 1-A1"
Notes Not an intention to treat anal$sis, cannot convert due to lack of data (ointervention:
#dditional s$stemic antibiotics were administered to patients in 5roup 1 and 9 patientsin 5roup for reasons other than infections at the operative site '#uthors stated the$
repeated the anal$sis e%cluded these patients and no si&nificant difference in the resultswere found*" #dverse dru& reactions: 5roup 1: episodes of pruritis and 5roup : 1 case
diarrhea and 1 case of d$spnea (ountr$: 0""
#llocationconcealment
#
S(#$+ B'"k'l'+ 0114
2ethods )andomi6ed trial, not blinded"
articipants #ll patients under&oin& (esarean section"
NB1-, patients e%cluded from the stud$ because of the followin& e%clusion criteria"C%clusion criteria: a&eE18, dru& aller&$, received antibiotics in last hours, received
steroids for fetal lun& maturit$ or medical illness, renal or hepatic d$sfunction, evidenceof +#+"
+nterventions 5roup 1: & cefota%ime in 1 L N b$ uterine lava&e"
5roup : 1 & cefota%ime iv after cord clamped with repeat dose at > and 1 hours"
/utcomes !ebrile morbidit$ 'temp .8 % occassions > hours apart, e%cludin& first hourspostpartum"
5roup 1: 9A
8/20/2019 Abprofilactico Cesarea
6/40
da$s, alcohol or dru& abuse"
+nterventions 5roup 1: & cefotetan iv after cord clamped, two additional doses of either cefotetan or
placebo were &iven at > and 1 hours after first in3ection"5roup : & cefo%itin as per re&imen above"
/utcomes !ailure rate '+nfectious morbidit$ included evidence of an$ infection includin&
endometritis, wound infection, pelvic abscess and FT, fever % also included .8*
5roup 1: 1-A111 vs 5roup : >A"
Notes (ountr$: (anada"
#llocation
concealment
#
S(#$+ Boo(*%+ 0125
2ethods )andomi6ed trial, table of random numbers used b$ circulatin& nurse to allocate patients"+ntention to treat anal$sis"
articipants #ll women under&oin& primar$ (A in a > month period"
C%clusion criteria: dru& aller&$, recent use of antibiotics 'not specified* or known
infectious process"
+nterventions 5roup 1: +ntraoperative irri&ation, cefo%itin & in 1L N, NB
8/20/2019 Abprofilactico Cesarea
7/40
4ound infection 'cellulitis andAor purulent draina&e*:
5roup 1: .A19 vs 5roup : .A18 vs 5roup : A94ound infection 'fever, er$thema, induration, tender andAor purulent draina&e fromwound*"
8/20/2019 Abprofilactico Cesarea
8/40
5roup 1: A> vs 5roup : -A9
Cndometritis 'fever or uterine tenderness withAwo foul lochia:
5roup 1: >A> vs 5roup : .A9
0T+ ' fever, d$suria and pos culture*"5roup 1:A> vs 5roup : -A9"
Notes (onverted stud$ to intention to treat model 'NB11>*, outcome of last women not
included in stud$ she underwent (esareanh$sterectom$"
#bove 0T+, wound infection and endometritis are distinct from @febrile morbidit$@"
(ountr$: 0""
#llocationconcealment
;
S(#$+ Das*o 0123
2ethods )andomi6ed, doubleblind control trial"
(omputer&enerated numbers usin& mi%ed con&ruential method"
+ntention to treat anal$sis"
articipants 4omen under&oin& (A between December 198 and 2a$ 198, all indications"
C%cusion criteria: dru& aller&$, antibiotic therap$, known infectious process"
+nterventions +rri&ation solutions: 'information from placebo arm e%cluded*" #ll solutions contained &
dru& in 8-- cc N with a vitamin added to each for dis&uise"
5roup 1: (ephapirin sodium5roup : (ephamandole nafate
5roup .: 2o%alactam disodium5roup : #mpicillin sodium"
/utcomes Cndometritis 'temp ."8, uterine tenderness, pelvic irritation without other locali6in&
si&ns5roup 1: 8A- vs 5roup : .A> vs 5roup .: 1.A9 vs 5roup : >A-"
0T+ ' 1--,--- or&s*
5roup 1:1A- vs 5roup : A> vs 5roup .: 1A9 vs 5roup :
8/20/2019 Abprofilactico Cesarea
9/40
+nterventions 5roup 1: 1 & iv cefa6olin after cord clamped and two further doses of 1 & iv at 8 hour
intervals 'nB*"
5roup : cefonicid 1 & after cord clamped 'nB1-.*"
/utcomes No wound infections"!ebrile morbidit$ 'temp ."8 % , hour apart, not first hours postoperation or
temp .8 first hours*
5roup 1: 18A9> vs 5roup : 1 vs 5roup : .A1-."
Notes Hospital sta$ 'mean*: 5roup 1: " da$s vs 5roup : " da$s"
(ountr$: 0""
#llocation
concealment
#
S(#$+ Ellio( 0127
2ethods )andomi6ed, placebo control, blinded 'mechanism not specified*"
(ode broken if postop infection developed"
lacebo data e%cluded from this review"
+ntention to treat"
articipants 4omen under&oin& (A"+nclusion: )/2, at least one FC
C%clusion : dru& aller&$, temperature .">, +#+"
+nterventions 5roup 1: #mpicillin & after cord clamped, then 1& iv 7>h until eatin&, then *"
/utcomes !ebrile morbidit$ 'temp ."8 %, > hours apart, e%cludin& first hours*:
8/20/2019 Abprofilactico Cesarea
10/40
5roup 1:.A. vs 5roup : 1"
Cndometritis 'fever, uterine tenderness, foul dischar&e*: 5roup 1: .A. vs 5roup :
1.A>"
0T+ 'fever, d$suria or pos culture*:5roup 1: -A. vs 5roup : 1A>"
4ound infection 'fever, cellulitis and e%udate*
5roup 1: -A. vs 5roup : 1A>"/ther serious infection 'FT, sepsis*:5roup 1: -A. vs 5roup : A>"
Notes 2ean duration of hospital sta$: 5roup 1: "1 da$s vs 5roup : hours apart, e%cludin& first hours postoperation*:
5roup 1: A.9 vs 5roup : .A vs 5roup .: A.8"No wound infections, or cases of sepsis"
Cndometritis 'fever, uterine tenderness, foul dischar&e, no other etiolo&$ apparent*:
5roup 1: A.9 vs 5roup : A vs 5roup .: A.8
0T+ 'fever, urinar$ s$mptoms or positive culture*:5roup 1: -A.9 vs 5roup : 1A vs 5roup .: -A.8"
Notes (ountr$: 0""
#llocation
concealment
;
S(#$+ Fa"o 0114
2ethods )andomi6ed trial"
Numbers in each treatment &roup unbalanced, reason &iven: stud$ is on&oin&,
randomi6ation not $et complete"
+ntention to treat anal$sis"
articipants 4omen for (A, indi&ent population, Harris count$, Te%as
+nclusion: labor hours, afebrile, no antibiotic therap$ in previous da$s"C%clusion: dru& aller&$
NB1
8/20/2019 Abprofilactico Cesarea
11/40
'cefo%itin 1&AnB1
8/20/2019 Abprofilactico Cesarea
12/40
Notes Lan&ua&e: !rench"
No information on hospital sta$, adverse dru& reactions or neonatal outcomes"
(ountr$: (anada"
#llocation
concealment
#
S(#$+ Galask 0122
2ethods )andomi6ed"Table of random numbers in :1 ratio so twice as man$ participants received cefotetan"
Not intention to treat, cannot convert"
articipants 4omen for primar$ or repeat (A"
+nclusion: a&e 18 and 1
hours after the first 'nB9*"
/utcomes Cndometritis 'criteria not specified*:5roup 1: 19A1> vs 5roup : A9"
4ound infection 'criteria not specified*:5roup 1: A1> vs 5roup : A9"
0T+ 'criteria not specified*:5roup 1: 1A1> vs 5roup : A9"
!ebrile morbidit$ 'criteria not specified*:
5roup 1: 1A1> vs 5roup : -A9"
Notes (ountr$: 0""
#llocation
concealment
;
S(#$+ Gall 0126
2ethods )andomi6ed, doubleblind"Not intention to treat, cannot convert due to lack of data"
articipants 4omen under&oin& primar$ (A presumed to be at increased risk"
+nclusion: labor or )/2 > hours, scalp clip 9 hours, +0(, . or more va&inal
e%aminations"
N B 1. e%cluded after randomi6ation due to errors in antibiotic administration"
+nterventions 5roup 1: iperacillin & iv after cord clamped 'nB>-*"5roup : iperacillin & iv after cord clamped and repeat same dose at and 8 hours
post first dose 'nB*"
/utcomes Cndometritis criteria not specified:
5roup 1: 8A>- vs 5roup : .A"
Notes (ountr$: 0""
8/20/2019 Abprofilactico Cesarea
13/40
#llocation
concealment
#
S(#$+ Gon'n 0123
2ethods )andomi6ed, doubleblind stud$"
Not intention to treat, cannot convert, data not supplied"
articipants 4omen under&oin& (A"
C%clusion: fever, infection in labor, antibiotic therap$ in last 8 hours, separate indicationfor proph$la%is, dru& aller&$"
NB 1 randomi6ed, 9 e%cluded due to protocol deviation"
+nterventions 5roup 1: (efamandole & in 1 l N, +rri&ation 'nB1-1*"
5roup : (efamandole & iv after cord clamped and repeat same dose 7>h % < doses
'nB1-*"
/utcomes Cndometritis 'temperature .8 % da$s, e%cludin& first hours, uterine tenderness,with or without foul lochia, no other obvious cause for infection*:
5roup 1:11A1-1 vs 5roup : 1 and 1hour postoperation 'nB
8/20/2019 Abprofilactico Cesarea
14/40
Not intention to treat, cannot convert"
articipants 4omen under&oin& (A"
+nclusion: a&e 18, no dru& aller&$, in labor or )/2 present"C%clusion: elective (A, current antibiotic therap$, chronic renal or hepatic disease"
+nterventions 5roup 1: (efa6olin 1 & iv after cord clamped 'NB>.*"
5roup : (efo%itin & iv after cord clamped 'NB>>*"
5roup .: (efota%ime 1 & iv after cord clamped 'NB>-*"
/utcomes Cndometritis 'temp elevation, uterine tenderness, foul lochia, leukoc$tosis 1. vs 5roup : 9A>> vs 5roup .: -"0T+: '. vs 5roup : -A>> vs 5roup .: -A>-";acteremia 'criteria not specified*:
5roup 1: A>. vs 5roup : 1A>. vs 5roup .: -A>-"
Notes (ountr$: 0""
#llocationconcealment
;
S(#$+ Ha"('"( 0126
2ethods )andomi6ed"
Not intention to treat anal$sis, cannot convert since data not included"
articipants 4omen under&oin& (A"
C%clusion: infection, antibiotic therap$ in last hours, temperature .8, dru& aller&$"
1
8/20/2019 Abprofilactico Cesarea
15/40
hepatic or renal disease"
NB189, vs 5roup : -"Cndometritis 'fever, foul li7uor, or uterine tenderness*
5roup 1: >A> vs 5roup : .A>-"0T+ 'fever, pos culture, with or without d$suria*:
5roup 1: A> vs 5roup : A>-"4ound infection 'fever, cellulitis, or e%udate*:
5roup 1: 1A> vs 5roup : 1A>-"
Notes (ountr$: (anada"
#llocationconcealment
#
S(#$+ I(sko)i(: 0161
2ethods tate women assi&ned at random accordin& to da$ of admission"
Three &roups of women, one a placebo &roup" /b3ective of this review is to comparedifferent re&imens, therefore, the data from the placebo arm is e%cluded"
articipants 4omen under&oin& (A for various reasons, NB1
8/20/2019 Abprofilactico Cesarea
16/40
+ntention to treat anal$sis"
lacebo arm and related data e%cluded due to ob3ectives of this review"
articipants 1-- women re7uirin& (AC%clusion: elective (A, )/2 E .h, or fewer va&inal e%ams, temperature .8, dru&
aller&$ )/2 hours"
+nterventions 5roup 1: (efa6olin 1 & iv after cord clamped 'nB
8/20/2019 Abprofilactico Cesarea
17/40
articipants #ll women became candidates when the decision was made to perform primar$ (A" #
few women for repeat (A became candidates if the$ presented with )/2, labor, obesit$
or chronic medical conditions associated with increased infectious risk"
C%clusion criteria: si&ns of infection 'temp ".8, +#+*, aller&$ to penAcephalosporin,antibiotic treatment in last 1 da$s, unable to obtain consent"
+nterventions NB1-"
5roup 1: 1 & cephalothin iv Ion call to /)I and a&ain two and ei&ht hours postoperation
'nB8*"
5roup : 1 & cefamandole iv, timin& of administration as above 'nB.*"
/utcomes !ebrile morbidit$ 'temperature .8 % da$s, e%cludin& first hours*5roup 18A8? 5roup 1A."
!ebrile morbidit$ 'above* then broken down b$ cause:Cndometritis 'fever, uterine tenderness*
5roup 1 1
8/20/2019 Abprofilactico Cesarea
18/40
#llocation
concealment
;
S(#$+ L'on'((i 0121
2ethods )andomi6ed, blinded, placebo control trial"
lacebo arm data e%cluded from this review"
+ntention to treat"
articipants atients for (A 'primar$, after onset of labor*"Lar&el$ a low socioeconomic, indi&ent population"
+nterventions 5roup 1: iperacillin & iv after cord clamped 'NBh 'NB
8/20/2019 Abprofilactico Cesarea
19/40
5roup : (ephapirin & in 1L N b$ irri&aiton 'NB*"
/utcomes Cndometritis 'temp 1--", uterine tenderness, foul lochia, no other cause for infection*:
5roup 1: 1A1 vs 5roup : A"4ound infection: No cases"
0T+ '1- e%p < or&sAml*: 5roup 1: A1 vs 5roup : 1A"
Notes 2ean hospital sta$: 5roup 1: "9 da$s vs 5roup : "8 da$s" No information on neonatal
morbidit$ or dru& reactions" (ountr$: 0""
#llocation
concealment
#
S(#$+ L'is 0114
2ethods )andomi6ed, doubleblind, control"
(ontrol arm data not included due to ob3ective of review"
Not intention to treat 'cannot convert*"
articipants +ndi&ent population of women under&oin& (A"NB.9>, 9 e%cluded due to incomplete charts"
C%clusion: antibiotic therap$ in last 1 da$s, dru& aller&$"
+nterventions 5roup 1: Ticarcillin < & in 1" L N, b$ irri&ation 'NB1 and 1 hours post
operation 'NB>-*"
5roup : (efa6olin 1 & iv after cord clamped and further doses at > and 1 hours post
operation 'NB-*"
5roup .: (efota%ime 1 & iv after cord clamped and further doses at > and 1 hours
postoperation 'NB
8/20/2019 Abprofilactico Cesarea
20/40
/utcomes Cndometritis 'temperature .8, foul lochia, uterine tenderness*: 5roup 1: A>- vs 5roup
: .A- vs 5roup .: A- vs 5roup : 1A- vs 5roup .: 1AA18 da$s" #lso recorded same for @failure
an$ infectious complication@: 5roup 1: 8"1 da$s vs 5roup : 8"1 da$s vs 5roup .:
"1 da$s"
(ountr$: (anada"
#llocation
concealment
#
S(#$+ Mans#'(o 0121
2ethods )andomi6ed trial"+ntention to treat"
articipants Nonelective (A"
C%clusion: dru& aller&$, renal d$sfunction, temperature .8, antibiotic therap$ in last 8
hours
+nterventions 5roup 1: +mipenem *"
/utcomes Cndometritis 'criteria not specified*: 5roup 1: 1A vs 5roup : 1A>"
!ebrile morbidit$ 'criteria not specified*: 5roup 1: -A vs 5roup : 1A>"
Notes Lan&ua&e: +talian" (ountr$: +tal$"
No data on hospital sta$, neonatal morbidit$ or dru& reactions"
#llocationconcealment
#
S(#$+ Mass' 0122
2ethods atient allocation b$ hospital +D number"
+ntention to treat"
articipants 4omen for nonelective (A, labor or )/2, NB
8/20/2019 Abprofilactico Cesarea
21/40
#llocation
concealment
(
S(#$+ Ma(*'li'" 0117
2ethods ub3ects alternatel$ assi&ned to treatment &roups"
+ntention to treat"
articipants 4omen for (A"
+ndi&ent population"C%clusion: +#+, evidence of other infection"
+nterventions 5roup 1: (efa6olin & iv after cord clamped and saline irri&ation of abdomen 'NB1*"
5roup : (efo%itin & iv and further doses at and 8 hours postoperativel$ 'NB*"
/utcomes Cndometritis 'temp .8, uterine tenderness, positive culture, no other identifiable cause
of infection*5roup 1: A> vs 5roup : A"
4ound infection 'no criteria stated*
5roup 1: A> vs 5roup : A"
0T+ 'no criteria stated* 5roup 1: 1A> vs 5roup : -A"
Notes (ountr$: 0""
2ean hospital sta$: 5roup 1: "< da$s vs 5roup : "< da$s"
#llocation
concealment
#
S(#$+ MG"'!o" 0122
2ethods )andomi6ed, multicentre trial"
8/20/2019 Abprofilactico Cesarea
22/40
4omen assi&ned in :1 ratio for cefotetan accordin& to computer &enerated
randomi6ation codes"
Not intention to treat 'cannot convert*
articipants #dults '18 *"
5roup : #s above e%actl$ but with addition of #mpicilin ' &* and tetrac$cline '1"< &* per
da$, to complete . da$s 'NB8*"
/utcomes !ebrile morbidit$ 'temperature .8 % occasion, hours apart, e%cludin& first hours*:
5roup 1: 1A9> vs 5roup : 11A8"
Cndometritis: 5roup 1: A9> vs 5roup : .A8"4ound infection: 5roup 1: vs 5roup : >A8"
0T+: 5roup 1: .A9> vs 5roup : 1A8"
'No criteria specified for above three*
/ther serious infection 'sepsis, pneumonia*:
5roup 1: 1A9> vs 5roup : 1A8"
Notes +ntervention not clear re&ardin& fre7uenc$ and route of antibiotics"No data on hospital sta$, neonatal morbidit$"
(ountr$: +srael"
#llocation
concealment
(
S(#$+ O-L'a"+ 0123
8/20/2019 Abprofilactico Cesarea
23/40
2ethods )andomi6ed, nonblind"
)andomi6ation done b$ hospital number"
+ntention to treat"
articipants 4omen under&oin& primar$ (A after onset of labor"
+ndi&ent population"C%clusion: febrile, dru& aller&$, infection present"
+nterventions 5roup 1: #mpicillin & iv @intraoperativel$@ and additional doses 7>h 'NB>1*"
5roup : #mpicillin & iv as above plus addition of 5entamicin 1m&Ak& after cord
clamped and 78h % > doses 'NB>*"
/utcomes !ebrile morbidit$ 'temperature ."9 %, > hours apart, at least hours post
operativel$*: 5roup 1: 19A>1 vs 5roup : 1A>"Cndometritis 'tender uterus, foul lochia, temperature ."9*:
5roup 1: 1.A>1 vs 5roup : "
4ound infection 'no criteria*:
5roup 1: 1A>1 vs 5roup : 1A>"
0T+ 'no criteria*: 5roup 1: 1A>1 vs 5roup : 1A>"
Notes 2ean hospital sta$: 5roup 1: >" da$s vs 5roup : "
+nfectious morbidit$ 'endometritis JA 0T+*:
5roup 1: 9A- vs 5roup : 8A>"4ound infection: 5roup 1: -A9- vs 5roup : 1A>"
Notes Discrepanc$ in numbers between &roups $et state @randomi6ed@"
(ountr$: 0""
#llocation
concealment
;
S(#$+ P'('"son 0114
2ethods )andomi6ed, doubleblind"
+ntention to treat"
8/20/2019 Abprofilactico Cesarea
24/40
articipants 4omen under&oin& nonelective (A 'defined as in labor with )/2*"
C%clusion: dru& aller&$, patient on antibiotics, those with evidence of infection, those
re7uirin& ;C proph$la%is"
+nterventions 5roup 1: (efa6olin & iv after cord clamped 'NB*"
5roup : (efamandole & iv after cord clamped 'NBA vs 5roup : >A
8/20/2019 Abprofilactico Cesarea
25/40
antibiotic therap$ in last da$s, @protocol failures@"
+nterventions 5roup 1: (efo%itin & iv after cord clamped 'NB>>*"
5roup : (efo%itin & iv after cord clamped and additional doses of 1& iv at > and 1hours postoperativel$ 'NB*"
/utcomes !ebrile morbidit$ 'temperature .8 for hours, e%cludin& first hours after (A*:
5roup 1: 19A>> vs 5roup : 11A"
Cndometritis 'fever, foul lochia, andAor uterine tenderness * 5roup 1:> vs 5roup :
1A"
4ound infection 'palpable induration, wound dehiscence andAor pus*:
5roup 1: A>> vs 5roup : 1A"0T+ '1- e%p < or&AmL*: 5roup 1: .A>> vs 5roup : -A"
Notes (ountr$: The Netherlands"
No data on hospital sta$, neonatal outcomes, dru& reactions"
#llocation
concealment
#
S(#$+ Sal(:man 0123
2ethods )andomi6ed double blind stud$, mechanism not stated"
articipants 1 hours"
C%clusion criteria: temperature .8, si&ns of active infection, antimicrobial use within last hours, dru& aller&$"
+nterventions 5roup 1: 2e6locillin & iv after cord clamped 'sin&le dru& dose*, nBA
8/20/2019 Abprofilactico Cesarea
26/40
articipants #ll women under&oin& (A with )/2 for . hours or more, all were 18 $ears of a&e"
C%clusion: dru& aller&$, antibiotic therap$ in last hours, women were @likel$@ to receive
other antibiotics, evidence of intrapartum infection"
+nterventions 5roup 1: (eforanide & iv after cord clamped 'NB.*"
5roup : (eforanide & in 1L N b$ irri&ation 'NB*"
/utcomes Cndometritis 'purulent cervical dischar&e, uterine tenderness, temperature .8*:
5roup 1: A. vs 5roup : .A"
4ound infection 'purulent draina&e from wound*
5roup 1: -A. vs 5roup : 1A"
0T+ '1- e%p < or&AmL with fever, d$suria, fre7uenc$ or (F# tenderness*: 5roup 1: A.vs 5roup : 1A"
!ebrile morbidit$ 'temperature .8 % da$s consecutivel$, e%cludin& first hours*:5roup 1: A. vs 5roup : >A"
Notes (ountr$: 0""
2ean hospital sta$: 5roup 1: " da$s vs 5roup : >" hour 'NB19*"
5roup : (efuro%ime
8/20/2019 Abprofilactico Cesarea
27/40
/utcomes Cndometritis 'uterine andAor adne%al tenderness, accompanied b$ fever with or without
purulent va&inal dischar&e: 5roup 1: >:
8/20/2019 Abprofilactico Cesarea
28/40
5roup 1: A- vs 5roup : -A9
Notes (ountr$: 0""
2ean hospital sta$: 5roup 1: >"1 da$s vs 5roup : >" da$s"
#llocation
concealment
;
S(#$+ ?'lls 0115
2ethods )andomi6ed trial, placebo control"
lacebo data e%cluded due to ob3ective of this review"+ntention to treat"
articipants 4omen under&oin& nonelective (A"
+nterventions 5roup 1: 2etronida6ole 1 & pr after cord clamped 'NB8*"
5roup : 2etronida6ole 1 & pr after cord clamped and (efuro%ime
8/20/2019 Abprofilactico Cesarea
29/40
#llocation
concealment
(
(diff B clostridia difficile(D B cephalopelvic disproportion(A B cesarean section+#+ B intraamniotic infection
+D B identit$+L B one litre+0( intrauterine pressure catheter+F B intravenousN B normal saline/ B b$ mouthH B ever$ four hours)/2 B rupture of membranes;C B subacute bacterial endocarditisFT B septic pelvic vein thrombophlebitis)+ B sur&icall$ related infection)/2 B spontaneous rupture of membranesFC B spontaneous va&inal e%amination0(L# B universit$ of (alifornia at Los #n&eles0T+ B urinar$ tract infection4;( B white blood cell count
M) B $ear
C*a"a('"is(is o/ '=l#$'$ s(#$i's
S(#$+ R'ason /o" '=l#sion
D@#n&elo
198-
(omparison of short versus lon&course proph$lactic antibiotic treatment:
#uthors do not list dose of dru& at time of first administration, nor do the$ indicate the time ofadministration 'preoperative, cord clamp* The authors are not even clear about the identit$ of
the dru& which be&ins the proph$lactic re&imen"The$ state that it is a random stud$ but provide no details of mechanism"
Dealma
198-
#t the start of the stud$, two arms? one a no treatment arm, the other composed of women
&iven either cefamandole or penicillin plus &entamicin" +t would have been possible to tr$ anddissect important information from the stud$ e%cept that the$ chan&ed the antibiotic re&imen
after treatin&
8/20/2019 Abprofilactico Cesarea
30/40
;oothb$ ), ;enrubi 5, !errell C" (omparison of intravenous cefo%itin proph$la%is with intraoperative cefo%itin irri&ation for theprevention of postcesareansection endometritis" G )eprod 2ed 198?9'11*:8.-8."
Ca"lson 0114 published data onl$O(arlson (, Duff " #ntibiotic proph$la%is for cesarean deliver$: is an e%tendedspectrum a&ent necessar$P" /bstet
5$necol 199-?>'.*:...>"
Cono)'" 0125 published data onl$O
(onover 4, 2oore T" (omparison of irri&ation and intravenous antibiotic proph$la%is at cesarean section" /bstet5$necol 198?>.'>*:891"
C"om%l'*olm' 0126 published data onl$O(rombleholme 4, 5reen G, /hmmith 2, Dahrou&e D, DeKa$ F, )ideout #, weet )" (esarean section proph$la%is: comparison
of two doses with three doses of me6locillin" #G)+2 198?1.:1?.1'1*:1
8/20/2019 Abprofilactico Cesarea
31/40
;ako%i 0122 published data onl$OGakobi , 4eissman #, Qimmer C, aldi C" in&ledose cefa6olin proph$la%is for cesarean section" #m G /bstet
5$necol 1988?1?9'1-*:181..>"
L')in 0128 published data onl$OLevin D, 5orchels (, #ndersoen )" )eduction of postcesarean section infectious morbidit$ b$ means of antibiotic irri&ation" #m G
/bstet 5$necol 198.?1'.*:.>"
L'is 0114 published data onl$OLewis D, /tterson 4, Dunnihoo D" #ntibiotic proph$lactic uterine lava&e in cesarean section: a doubleblind comparison of saline,
ticarcillin and cefo%itin irri&ation in indi&ent patients" 2ed G 199-?8.'.*:>"
Lo#i' 0127 published data onl$OLouie TG, ;inns ;, ;askett T, )oss G, Koss G" (efota%ime, cefa6olin or ampicillin proph$la%is of febrile morbidit$ in emer&enc$
cesarean sections" (lin Therap 198?"
Mans#'(o 0121 published data onl$O2ansueto 5, Tomaselli !" Rrofilassi antibiotica in pa6ieti sottoposte a ta&lio cesareo non di ele6ione con +mipenem in Isin&le
doseI versus cefota%ime in Imultiple dosesIS" Cur )ev 2ed harm c 1989?11:>8"
Mass' 0122 published data onl$O
2asse #, Tur&eon , 5a$ N, Ferschelden 5" RCfficacite comparee de l@antibiotproph$la%iie par la cefo%itine en une ou trois dosesdans la cesarienneS" (an 2ed #ssoc G 1988?1.8:919"
Ma(*'li'" 0117 published data onl$O2athelier #" # comparison of postoperative morbidit$ followin& proph$lactic antibiotic administration b$ combined irri&ation andintravenous route or b$ intravenous route alone durin& cesarean section" G erinat 2ed 199?-:118"
MG"'!o" 0123 published data onl$O2c5re&or G, !rench G, 2akowski C" in&ledose cefotetan versus multidose cefo%itin for proph$la%is in cesarean section in hi&h
risk patients" #m G /bstet 5$necol 198>?1
8/20/2019 Abprofilactico Cesarea
32/40
)oe% #, u$enbroek G, vanLoenen #, #rts N" in&le versus threedose cefo%itin proph$la%is in caesarean section: a randomi6edclinical trial" Cur G /bstet 5$necol )eprod ;iol 198??.1:-91"
Sa"a)ola(: 0129 published data onl$O
aravolat6 L, Lee (, Drukker ;" (omparison of intravenous administration with intrauterine irri&ation with ceforanide fornonelective cesarean section" /bstet 5$necol 198>'*::>->>"
)eferences to studies awaitin& assessment
Ba*'"ai' 0116 ;aheraie #, 2odares 2, #6imi Kh, 2ahmodi 2" in&ledose cefa6olin proph$la%is for cesarean section" #cta /bstet 5$necol
cand 199?>:8"
L#((k#s 0116 Luttkus #, !iebelkorn G, Dudenhausen 4" #ntibiotic proph$la%is in cases of emer&enc$ caesarean section 'translated*" 5eburtsh u
!rauenheilk 199?
8/20/2019 Abprofilactico Cesarea
33/40
D#// 0127 Duff , mith N, Keiser G!" #ntibiotic proph$la%is in low risk cesarean section" G )eprod 2ed 198?:1..1.8"
Gi%%s 0167 5ibbs ), De(herne$ #H, chwar6 )H" roph$lactic antibiotics in cesarean section: a doubleblind stud$" #m G /bstet
5$necol 19?11:1-81-
8/20/2019 Abprofilactico Cesarea
34/40
47 0s( G'n'"a(ion C'p*alospo"in )s 7n$@8"$ G'n'"a(ion C'p*alospo"in
/utcome title
No" of
studies
No" of
participants
tatistical
method Cffect si6e
-1 !ebrile 2orbidit$ < 1--8 eto /) R9
8/20/2019 Abprofilactico Cesarea
35/40
47 0s( G'n'"a(ion C'p*alospo"in )s 7n$@8"$ G'n'"a(ion C'p*alospo"in
/utcome title
No" of
studies
No" of
participants
tatistical
method Cffect si6e
-1 !ebrile 2orbidit$ < 1--8 eto /) R9 R-">8,
."8S
8/20/2019 Abprofilactico Cesarea
36/40
47 0s( G'n'"a(ion C'p*alospo"in )s 7n$@8"$ G'n'"a(ion C'p*alospo"in
/utcome title
No" of
studies
No" of
participants
tatistical
method Cffect si6e
-1 !ebrile 2orbidit$ < 1--8 eto /) R9 R-"8.,
"18S
- Cndometritis 1 1. eto /) R9,
""S
- 0rinar$ Tract +nfection 1 1. eto /) R9,
1>"S
41 Ca"%ap'n'm )s 7n$@8"$ G'n'"a(ion C'p*alospo"in
/utcome title
No" of
studies
No" of
participants
tatistical
method Cffect si6e
-1 !ebrile 2orbidit$ 1 8 eto /) R9
8/20/2019 Abprofilactico Cesarea
37/40
47 0s( G'n'"a(ion C'p*alospo"in )s 7n$@8"$ G'n'"a(ion C'p*alospo"in
/utcome title
No" of
studies
No" of
participants
tatistical
method Cffect si6e
-1 !ebrile 2orbidit$ < 1--8 eto /) R9S
-. 4ound +nfection . S
- Cndometritis 8 9.1 eto /) R9
8/20/2019 Abprofilactico Cesarea
38/40
47 0s( G'n'"a(ion C'p*alospo"in )s 7n$@8"$ G'n'"a(ion C'p*alospo"in
/utcome title
No" of
studies
No" of
participants
tatistical
method Cffect si6e
-1 !ebrile 2orbidit$ < 1--8 eto /) R9>- eto /) R9
8/20/2019 Abprofilactico Cesarea
39/40
Title
An(i%io(i p"op*+la=is "'!im'ns an$ $"#!s /o"
'sa"'an s'(ion
)eviewer's* Hopkins L, Smaill F
(ontribution of reviewer's* +nformation not supplied b$ reviewer
+ssue protocol first published 1998A.
+ssue review first published 1999A
Date of most recent amendment +nformation not available
Date of most recent 0;T#NT+FC
amendment
1 November 1998
2ost recent chan&es +nformation not supplied b$ reviewer
Date new studies sou&ht but none found +nformation not supplied b$ reviewer
Date new studies found but not $et
includedAe%cluded
+nformation not supplied b$ reviewer
Date new studies found and
includedAe%cluded
+nformation not supplied b$ reviewer
Date reviewers@ conclusions section
amended
+nformation not supplied b$ reviewer
(ontact address Dr !iona maill
rofessor
Department of atholo&$ and 2olecular 2edicine
!acult$ of Health ciences, 2c2aster 0niversit$
)oom N91-- 2ain treet 4est
Hamilton
L8N .Q</ntario
(#N#D#
J1 9-<
8/20/2019 Abprofilactico Cesarea
40/40
Cditorial &roup code H2)C5
S O U R C E S O F S U P P O R T
E=('"nal so#"'s o/ s#ppo"(
No sources of support supplied
In('"nal so#"'s o/ s#ppo"(
No sources of support supplied
I n d e x T e r !
M'$ial S#%&'( H'a$in!s M'SH
#ntibiotic roph$la%is ? (esarean ection 2esh check words: !emale Human re&nanc$
U 0pdate oftware Ltd"#ll ri&hts reserved" No part of the data or procedures or pro&rams used for access to or the displa$ of the data in The
Cochrane Library ma$ be reproduced, chan&ed, translated, stored in a retrieval s$stem or transmitted in an$ form or b$an$ means without the prior permission of 0pdate oftware Ltd", e%cept in the case of copies intended for securit$backups or internal use"
http://parent.meshsinglesearch%28%22antibiotic%20prophylaxis%22%29/http://parent.meshsinglesearch%28%22cesarean%20section%22%29/http://parent.meshsinglesearch%28%22female%22%29/http://parent.meshsinglesearch%28%22female%22%29/http://parent.meshsinglesearch%28%22human%22%29/http://parent.meshsinglesearch%28%22pregnancy%22%29/http://parent.meshsinglesearch%28%22antibiotic%20prophylaxis%22%29/http://parent.meshsinglesearch%28%22cesarean%20section%22%29/http://parent.meshsinglesearch%28%22female%22%29/http://parent.meshsinglesearch%28%22human%22%29/http://parent.meshsinglesearch%28%22pregnancy%22%29/